证券代码：300253 证券简称：卫宁健康 公告编号：2024-036 卫宁健康科技集团股份有限公司 关于参股公司卫宁科技股权转让及增资进展 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 卫宁健康科技集团股份有限公司（以下简称"公司"）参股公司上 海金仕达卫宁软件科技有限公司（以下简称"卫宁科技"）为进一步优 化股权结构，壮大资本实力，大力发展商/医保智能风控和数据等业务， 通过股权转让及增资扩股的方式引入新投资人，其中，公司以人民币 7,500 万元向新投资人转让卫宁科技注册资本合计 252.0162 万元；新 投资人以人民币 22,500.00 万元认缴卫宁科技新增注册资本合计 614.4184 万元；卫宁科技员工持股平台以人民币 1,294.8502 万元认 缴卫宁科技新增注册资本 539.5209 万元。上述交易完成后，卫宁科技 注册资本由 6,553.5015 万元变更为 7,707.4408 万元，公司持有卫宁 科技的股权由 36.82%变更为 28.04%。具体内容详见 2023 年 4 月 25 日 披露于巨潮资讯网的《关于参股公司上海金仕达 ...

Investment Rating - The report maintains an "Outperform" rating for the company [3][41]. Core Insights - The company reported a revenue of 3.163 billion yuan for 2023, a year-on-year increase of 2.28%, while the net profit attributable to shareholders reached 358 million yuan, a significant increase of 229.49% [3][24]. - The gross margin improved to 45.0%, up 1.31 percentage points from the previous year, driven by an increase in the proportion of high-margin medical IT business [7][22]. - The company continues to expand its digital health services, with over 10,000 medical institutions served by its platform by the end of 2023, and a monthly active user count exceeding 24 million [11][35]. Financial Performance - The medical IT business grew by 12.66% year-on-year, while the internet healthcare segment saw a decline of 44.53% due to restructuring efforts [25][34]. - The company’s cost control measures were effective, with a sales expense ratio of 14.53%, down 1.51 percentage points, and a management expense ratio of 6.2%, down 0.67 percentage points [17][25]. - The forecast for 2024-2025 revenue has been adjusted to 3.654 billion and 4.167 billion yuan, respectively, with net profit estimates revised to 477 million and 670 million yuan [41][36]. Business Developments - The company launched the WiNGPT AI model in October 2023, marking a significant step in integrating AI into healthcare [40][35]. - The company is focusing on upgrading its core WiNEX product series to enhance its offerings in smart hospitals and digital health [28][35]. - The company has signed contracts worth 268 million yuan in the reporting period, reflecting a year-on-year growth of 122% in its insurance intelligent risk control and data + AI services [11][41].

Investment Rating - The report maintains a "Recommended" rating for the company [5]. Core Insights - The company's revenue for 2023 reached 3.163 billion, a year-on-year increase of 2.28%, while the net profit attributable to shareholders was 358 million, showing a significant growth of 229.49% [5]. - The healthcare information technology business saw a slight increase in new orders, with revenue growing by 12.66% to 2.849 billion in 2023 [6]. - The gross profit margin improved to 45%, up by 1.31 percentage points from the previous year, attributed to the increasing proportion of high-margin healthcare information technology revenue [7]. - The "1+X" strategy continues to evolve, with the WiNEX product line supporting high-quality development in hospital digital transformation [8]. Financial Performance Summary - In 2023, the company achieved a revenue of 3.163 billion, with a growth rate of 2.28% [11]. - The net profit attributable to shareholders was 358 million, reflecting a growth rate of 229.49% [11]. - The company expects revenues of 3.736 billion, 4.349 billion, and 4.907 billion for 2024, 2025, and 2026, respectively, with growth rates of 18.1%, 16.4%, and 12.8% [8]. - The projected net profit for the same years is 563 million, 716 million, and 857 million, with growth rates of 57.4%, 27.2%, and 19.6% [8].

| --- | --- | --- | --- | --- | --- | --- | --- | |----------------------------|----------------------------------------------------------------------------------------------------------------------------------|----------------------------------|------------------------------------------------|----------------|----------------|-----------------------------------------------------------------------|-----------------------| | [Table_Title] | 卫宁健康（ | 300253.SZ | ） | | [ | 公司评级 Table_Invest] | 证券研究报告 \n买入 | | | ...

证券研究报告 2024 年 04 月 20 日 卫宁健康(300253) 盈利恢复，有望受益新一代 WiNEX 和 WiNGPT 推广 事件： 卫宁健康发布 2023 年年度报告，2023 年公司实现营收 31.63 亿元，同比 增长 2.28%；归母净利润 3.58 亿元，同比增长 229.49%；扣非归母净利润 3.33 亿元，同比增长 178.51%；毛利率为 45.00%，同比提升 1.31pct。单 季度来看，第四季度公司实现营收 12.62 亿元，同比增长 3.32%；归母净利 润 2.06 亿元，同比由亏转盈；扣非归母净利润 2.43 亿元，同比由亏转盈； 毛利率为 49.29%，同比提升 7.31pct。 ➢ 医卫信息化软件销售及技术服务营收占比提升 2023 年，公司医疗卫生信息化业务收入同比增长 12.66%，营收占比为 90.05%，同比提升 8.30pct，其中：核心产品软件销售及技术服务业务收入 同比增长 14.59%，营收占比为 74.95%，同比提升 8.05pct；硬件销售业务 收入同比增长 4.00%，营收占比为 15.10%，同比提升 0.25pct。互联网医疗 健康业务收 ...

证券代码：300253 证券简称：卫宁健康 公告编号：2024-035 卫宁健康科技集团股份有限公司 关于取得发明专利证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 卫宁健康科技集团股份有限公司（以下简称"公司"）近日取得 由国家知识产权局颁发的一项发明专利证书。具体情况如下： | 专利名称 | 专利号 | 专利 申请 | 专利 | | 摘要 | | --- | --- | --- | --- | --- | --- | | | | 日 | 权人 | | | | | | | | | 本申请提供一种医疗信息整合方法、装置、计 | | | | | | | 算机设备、介质及系统，涉及医疗信息管理技 | | | | | | | 术领域。该医疗信息整合方法包括：第一机构 | | | | | | | 设备根据患者唯一属性信息，计算第一属性值； | | | | | 卫 | 宁 | 第一机构设备将第一属性值通过区块链设备发 | | 医 疗 信 息 | | 2021 | 健 | 康 | 送至第二机构设备，使得第二机构设备从区块 | | 整合方法、 | | | 科 | ...

Market Presence and Client Base - The company serves over 6,000 healthcare institutions, including more than 400 tertiary hospitals, covering 32 provinces and regions in China[34] - The new WiNEX product has expanded to hundreds of clients nationwide, establishing benchmark clients in various regions[35] - The company aims to enhance market share by leveraging successful implementations of the WiNEX product across various hospitals nationwide, focusing on the demand for smart hospital solutions[175] - The company is actively expanding its brand influence in response to public hospital reforms and the high-quality development of regional medical resources[175] Financial Performance - The company reported a total revenue of approximately CNY 4.2 billion for 2023, with a quarterly breakdown showing Q4 revenue at CNY 1.26 billion, marking a significant increase compared to previous quarters[57] - The net profit attributable to shareholders for Q3 2023 was CNY 205.62 million, while the net loss for Q4 was CNY 31.39 million, indicating fluctuations in profitability throughout the year[57] - Revenue from the healthcare information industry reached ¥2,848,601,352.19, with a year-on-year increase of 12.66%[60] - The company's operating revenue for 2023 reached ¥3,163,424,802.81, representing a 2.28% increase compared to ¥3,092,864,688.21 in 2022[190] - Net profit attributable to shareholders for 2023 was ¥357,959,124.85, a significant increase of 229.49% from ¥108,436,489.10 in 2022[190] Research and Development - R&D investment for the year reached CNY 697 million, accounting for 22.04% of total revenue, reflecting the company's commitment to innovation[55] - The company launched the WiNGPT medical vertical model and integrated it into over 100 clinical application scenarios, enhancing operational efficiency and quality of care[55] - The company is currently developing a new generation of health management software aimed at enhancing market competitiveness and expanding its product line[67] - The company is committed to increasing R&D investment and tracking industry trends to maintain competitive advantages[155] Strategic Initiatives - The company plans to enhance market efforts and improve communication with clients to reduce project implementation time and collection delays[7] - The company is pursuing strategic mergers and acquisitions, including the acquisition of 100% equity in Global Medical by its subsidiary, enhancing its market presence[53] - The company has implemented a "Quality and Return Dual Improvement" action plan to ensure sustainable development and long-term investment value[134] - The company is focusing on expanding its marketing service network to enhance service capabilities[152] Technology and Innovation - The company focuses on the "Internet + healthcare" sector to drive growth and innovation[36] - The company has implemented measures to enhance data security and personal information protection in line with new regulations on generative AI[27] - The company is committed to accelerating the R&D of the WiNEX series products, emphasizing innovation in specialized applications and intelligent adaptations[175] - The company has initiated a digital upgrade of its products and technologies to adapt to market competition in the healthcare industry[102] Cash Flow and Investments - The net cash flow from operating activities was ¥184,799,838.70, showing an 83.99% increase year-on-year[70] - The company reported a gain from the disposal of non-current assets amounting to CNY 57.53 million in 2023, a significant recovery from a loss of CNY 19.54 million in 2022[41] - The total amount of funds raised through the issuance of convertible bonds was 970.265 million, with a net amount of 961.210 million after deducting issuance costs[115] - The company has allocated ¥1,700.86 million of surplus fundraising to supplement working capital for daily operations and business development[101] Risks and Challenges - The company faces risks from intensified industry competition and management challenges due to scale expansion[141] - The company acknowledges various risks, including technology and product development risks, talent loss risks, industry competition risks, management risks, and seasonal performance fluctuations[164] - The company faces potential risks related to goodwill impairment if acquired assets do not meet future operational and profitability expectations, which could adversely affect current earnings[161] Future Outlook - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[190] - The company has outlined its future development outlook and strategic plans, emphasizing the need for investor awareness of the differences between plans, forecasts, and commitments[164] - The company aims to leverage medical data value to drive industry transformation and development[197]

卫宁健康科技集团股份有限公司 2023 年度独立董事述职报告 本人姚宝敬，男，1976 年出生，中国国籍，无境外永久居留权。复旦大学软 件工程专业硕士、高级工程师。历任上海市软件行业协会业务主管、副秘书长、 常务副秘书长、秘书长。现任上海市软件行业协会秘书长，兼任上海古鳌电子科 技股份有限公司独立董事，安科瑞电气股份有限公司独立董事，网宿科技股份有 限公司监事。自 2018 年 3 月起担任公司独立董事，董事会提名委员会主任委员， 董事会薪酬与考核委员会委员。 一、基本情况 报告期内，本人符合《上市公司独立董事管理办法》第六条对独立董事独立 性的要求，不存在影响独立性的情况。 二、年度履职概况 （一）出席董事会、股东大会情况 （姚宝敬） 2023 年，公司召开 13 次董事会，本人均亲自出席，无缺席或连续两次未亲 自出席会议的情况；公司召开 4 次股东大会，本人列席参加 2 次。具体出席董事 会、股东大会的情况如下： 各位股东及股东代表： 2023 年度，作为卫宁健康科技集团股份有限公司（以下简称"公司"）的独 立董事，本人严格按照《公司法》《证券法》《上市公司独立董事管理办法》《深 圳证券交易所上市公司自律 ...

国泰君安证券股份有限公司 关于卫宁健康科技集团股份有限公司 2023年度持续督导跟踪报告 | 保荐机构名称：国泰君安证券股份有限公司 | 被保荐公司简称：卫宁健康（300253.SZ） | | --- | --- | | 保荐代表人姓名：王雪萍 | 联系电话：021-38032704 | | 保荐代表人姓名：樊愈波 | 联系电话：021-38677656 | 一、保荐工作概述 二、保荐机构发现公司存在的问题及采取的措施 | 事项 | 存在的问题 | 采取的措施 | | --- | --- | --- | | 1.信息披露 | 无 | 不适用 | | 2.公司内部制度的建立和执 行 | 无 | 不适用 | | 3."三会"运作 | 无 | 不适用 | | 4.控股股东及实际控制人变 动 | 无 | 不适用 | | 5.募集资金存放及使用 | 无 | 不适用 | | 6.关联交易 | 无 | 不适用 | | 7.对外担保 | 无 | 不适用 | | 8.收购、出售资产 | 无 | 不适用 | | 9.其他业务类别重要事项 | 无 | 不适用 | | （包括对外投资、风险投 | | | 2 | 资、委托理财、财务资 ...

卫宁健康科技集团股份有限公司 2023 年度内部控制自我评价报告 卫宁健康科技集团股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要 求（以下简称"企业内部控制规范体系"），结合卫宁健康科技集团股份有限公 司（以下简称"公司"）内部控制制度和评价办法，在内部控制日常监督和专项 监督的基础上，我们对公司 2023 年 12 月 31 日（内部控制评价报告基准日）的 内部控制有效性进行了评价。 一、重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其 有效性，并如实披露内部控制评价报告是公司董事会的责任。监事会对董事会建 立和实施内部控制进行监督。经理层负责组织领导公司内部控制的日常运行。公 司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存在任何虚假 记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个 别及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及 相关信息真实完整，提高经营效率和效果，促进实现发展战略。由于内部控制存 在的固有局限性，故仅能为实现上述目标提供合理保证。此外，由于 ...